A Phase 3 interventional study of 15 mg E4/3 mg DRSP in Contraception, sponsored by Estetra. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.
Sponsored by Estetra · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 18 to 50 years.
Estetra is the lead sponsor of 15 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15 mg E4/3 mg DRSP tablet
Drug: 15 mg E4/3 mg DRSP
Drug pages: Estetrol · Drospirenone
15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
Also known as: 15 mg estetrol and 3 mg drospirenone
The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)
The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)
The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)
The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)
Number of Subjects With Unscheduled Bleeding/Spotting
Unscheduled bleeding/spotting is defined as any bleeding/spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding.
Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)
Number of Unscheduled Bleeding Days Per Cycle
Unscheduled bleeding is defined as any bleeding that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.
Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)
Number of Unscheduled Spotting Days Per Cycle
Unscheduled spotting is defined as any spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.
Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)
Number of Subjects With Absence of Scheduled Bleeding and/or Spotting
Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.
Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)
Number of Scheduled Bleeding and/or Spotting Days Per Cycle
Scheduled bleeding and /or spotting is defined as any bleeding and/or spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.
Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)
Number of Subjects With Abnormal Vital Signs
Vital signs included sitting systolic and diastolic blood pressures, and heart rate.
Time frame: From screening to end of treatment (12 months)
Number of Subjects With Abnormal Laboratory Assessment Results
Laboratory assessment included blood hematology, biochemistry, and lipids
Time frame: From screening to end of treatment (12 months)
Number of Subjects With Abnormal Physical Examination Results
Physical examinations included an evaluation of body as a whole, skin, head, eyes, ears, nose, and throat, neck, cardiovascular, respiratory, musculoskeletal, neurologic, lymphatic/thyroid, abdomen. When reporting the results of the physical examination, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.
Time frame: From screening to end of treatment (12 months)
Number of Subjects With Abnormal Gynecological Examination Results
Gynecological examinations included breast examination (performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external genitalia. When reporting the results, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.
Time frame: From screening to end of treatment (12 months)
Endometrial Biopsy Histology at Screening and End of Treatment
Endometrial biopsies was obtained from a subset of subjects included in the endometrial safety substudy at the screening visit and at the end of treatment visit if the subject has completed at least 10 cycles.
Time frame: Baseline and end of treatment (up to 13 cycles with 1 cycle = 28 days)
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)
The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".
Time frame: Baseline and Cycle 13 (1 cycle = 28 days)
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week
The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".
Time frame: Baseline and Cycle 13 (1 cycle = 28 days)
Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)
The MDQ is a standard method for measuring cyclical perimenstrual symptoms. The participants rated common symptoms and feelings associated with menstruation using the following scale: 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong),and 4 (present, severe) observed during pre-menstrual (4 days before menstruation), menstrual (most recent flow) and intermenstrual (remainder of the cycle) phases. Reported values are values at Cycle 13 minus values at Baseline. An overall positive change from baseline represents an increase in symptom or feeling severity.
Time frame: Baseline and Cycle 13 (1 cycle = 28 days)
| Milestone | 15 mg E4/3 mg DRSP |
|---|---|
| Started | 1553 |
| Completed | 1218 |
| Not completed | 335 |
| Withdrew: Lost to follow-up | 41 |
| Withdrew: Adverse event not related to bleeding | 104 |
| Withdrew: Adverse event related to bleeding | 53 |
| Withdrew: Protocol violation | 11 |
| Withdrew: Pregnancy | 7 |
| Withdrew: Pregnancy wish | 15 |
| Withdrew: Withdrawal by subject | 78 |
| Withdrew: Other | 26 |
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
| Pearl Index | 15 mg E4/3 mg DRSP |
|---|---|
| The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening | 0.47 (0.15 to 1.11) |
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
| Method failure Pearl Index | 15 mg E4/3 mg DRSP |
|---|---|
| The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening | 0.29 (0.06 to 0.83) |
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
| Pearl Index | 15 mg E4/3 mg DRSP |
|---|---|
| The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years) | 0.41 (0.13 to 0.96) |
On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.
| Method Failure Pearl Index | 15 mg E4/3 mg DRSP |
|---|---|
| The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years) | 0.25 (0.05 to 0.72) |
Unscheduled bleeding/spotting is defined as any bleeding/spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding.
| Participants | 15 mg E4/3 mg DRSP |
|---|---|
| Cycle 1 | 354 |
| Cycle 2 | 282 |
| Cycle 3 | 250 |
| Cycle 4 | 249 |
| Cycle 5 | 238 |
| Cycle 6 | 207 |
| Cycle 7 | 170 |
| Cycle 8 | 202 |
| Cycle 9 | 182 |
| Cycle 10 | 168 |
| Cycle 11 | 155 |
| Cycle 12 | 154 |
Unscheduled bleeding is defined as any bleeding that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.
| Days | 15 mg E4/3 mg DRSP |
|---|---|
| Cycle 1 | 0.2 ± 0.89 |
| Cycle 2 | 0.1 ± 0.66 |
| Cycle 3 | 0.1 ± 0.67 |
| Cycle 4 | 0.2 ± 0.79 |
| Cycle 5 | 0.1 ± 0.70 |
| Cycle 6 | 0.1 ± 0.80 |
| Cycle 7 | 0.1 ± 0.68 |
| Cycle 8 | 0.1 ± 0.72 |
| Cycle 9 | 0.1 ± 0.70 |
| Cycle 10 | 0.1 ± 0.61 |
| Cycle 11 | 0.1 ± 0.72 |
| Cycle 12 | 0.1 ± 0.68 |
Unscheduled spotting is defined as any spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.
| Days | 15 mg E4/3 mg DRSP |
|---|---|
| Cycle 1 | 0.8 ± 1.99 |
| Cycle 2 | 0.5 ± 1.50 |
| Cycle 3 | 0.5 ± 1.46 |
| Cycle 4 | 0.5 ± 1.55 |
| Cycle 5 | 0.5 ± 1.35 |
| Cycle 6 | 0.4 ± 1.24 |
| Cycle 7 | 0.4 ± 1.17 |
| Cycle 8 | 0.4 ± 1.19 |
| Cycle 9 | 0.4 ± 0.13 |
| Cycle 10 | 0.4 ± 1.25 |
| Cycle 11 | 0.3 ± 1.18 |
| Cycle 12 | 0.4 ± 1.23 |
Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.
| Participants | 15 mg E4/3 mg DRSP |
|---|---|
| Cycle 1 | 84 |
| Cycle 2 | 90 |
| Cycle 3 | 105 |
| Cycle 4 | 83 |
| Cycle 5 | 91 |
| Cycle 6 | 91 |
| Cycle 7 | 90 |
| Cycle 8 | 103 |
| Cycle 9 | 92 |
| Cycle 10 | 89 |
| Cycle 11 | 80 |
| Cycle 12 | 94 |
Scheduled bleeding and /or spotting is defined as any bleeding and/or spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.
| Days | 15 mg E4/3 mg DRSP |
|---|---|
| Cycle 1 | 6.1 ± 4.95 |
| Cycle 2 | 5.3 ± 3.62 |
| Cycle 3 | 5.2 ± 3.99 |
| Cycle 4 | 5.0 ± 3.14 |
| Cycle 5 | 4.9 ± 3.43 |
| Cycle 6 | 4.9 ± 3.34 |
| Cycle 7 | 4.7 ± 2.80 |
| Cycle 8 | 4.8 ± 3.85 |
| Cycle 9 | 4.7 ± 2.87 |
| Cycle 10 | 4.6 ± 2.69 |
| Cycle 11 | 4.7 ± 3.16 |
| Cycle 12 | 4.6 ± 2.97 |
Vital signs included sitting systolic and diastolic blood pressures, and heart rate.
| Participants | 15 mg E4/3 mg DRSP |
|---|---|
| Number of Subjects With Abnormal Vital Signs | 15 |
Laboratory assessment included blood hematology, biochemistry, and lipids
| Participants | 15 mg E4/3 mg DRSP |
|---|---|
| Number of Subjects With Abnormal Laboratory Assessment Results | 55 |
Physical examinations included an evaluation of body as a whole, skin, head, eyes, ears, nose, and throat, neck, cardiovascular, respiratory, musculoskeletal, neurologic, lymphatic/thyroid, abdomen. When reporting the results of the physical examination, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.
| Participants | 15 mg E4/3 mg DRSP |
|---|---|
| Body as a whole - Baseline — Normal | 1548 |
| Body as a whole - Baseline — Abnormal | 5 |
| Body as a whole - Baseline — Not done | 0 |
| Body as a whole - EOT — Normal | 1493 |
| Body as a whole - EOT — Abnormal | 5 |
| Body as a whole - EOT — Not done | 0 |
| Skin - Baseline — Normal | 1537 |
| Skin - Baseline — Abnormal | 16 |
| Skin - Baseline — Not done | 0 |
| Skin - EOT — Normal | 1,476 |
| Skin - EOT — Abnormal | 22 |
| Skin - EOT — Not done | 0 |
| Head, Eyes, Ears, Nose and Throat - Baseline — Normal | 1,543 |
| Head, Eyes, Ears, Nose and Throat - Baseline — Abnormal | 10 |
| Head, Eyes, Ears, Nose and Throat - Baseline — Not done | 0 |
| Head, Eyes, Ears, Nose and Throat - EOT — Normal | 1,492 |
| Head, Eyes, Ears, Nose and Throat - EOT — Abnormal | 3 |
| Head, Eyes, Ears, Nose and Throat - EOT — Not done | 3 |
| Neck - Baseline — Normal | 1,552 |
| Neck - Baseline — Abnormal | 1 |
| Neck - Baseline — Not done | 0 |
| Neck - EOT — Normal | 1,495 |
| Neck - EOT — Abnormal | 1 |
| Neck - EOT — Not done | 2 |
| Cardiovascular - Baseline — Normal | 1,553 |
| Cardiovascular - Baseline — Abnormal | 0 |
| Cardiovascular - Baseline — Not done | 0 |
| Cardiovascular - EOT — Normal | 1,496 |
| Cardiovascular - EOT — Abnormal | 1 |
| Cardiovascular - EOT — Not done | 1 |
| Respiratory - Baseline — Normal | 1,551 |
| Respiratory - Baseline — Abnormal | 2 |
| Respiratory - Baseline — Not done | 0 |
| Respiratory - EOT — Normal | 1,496 |
| Respiratory - EOT — Abnormal | 1 |
| Respiratory - EOT — Not done | 1 |
| Musculoskeletal - Baseline — Normal | 1,553 |
| Musculoskeletal - Baseline — Abnormal | 0 |
| Musculoskeletal - Baseline — Not done | 0 |
| Musculoskeletal - EOT — Normal | 1,495 |
| Musculoskeletal - EOT — Abnormal | 1 |
| Musculoskeletal - EOT — Not done | 2 |
| Neurologic - Baseline — Normal | 1,553 |
| Neurologic - Baseline — Abnormal | 0 |
| Neurologic - Baseline — Not done | 0 |
| Neurologic - EOT — Normal | 1,494 |
| Neurologic - EOT — Abnormal | 2 |
| Neurologic - EOT — Not done | 2 |
| Lymphatic/Thyroid - Baseline — Normal | 1,549 |
| Lymphatic/Thyroid - Baseline — Abnormal | 2 |
| Lymphatic/Thyroid - Baseline — Not done | 2 |
| Lymphatic/Thyroid - EOT — Normal | 1,494 |
| Lymphatic/Thyroid - EOT — Abnormal | 1 |
| Lymphatic/Thyroid - EOT — Not done | 3 |
| Abdomen - Baseline — Normal | 1,553 |
| Abdomen - Baseline — Abnormal | 0 |
| Abdomen - Baseline — Not done | 0 |
| Abdomen - EOT — Normal | 1,496 |
| Abdomen - EOT — Abnormal | 1 |
| Abdomen - EOT — Not done | 1 |
Gynecological examinations included breast examination (performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external genitalia. When reporting the results, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.
| Participants | 15 mg E4/3 mg DRSP |
|---|---|
| Breast - Baseline — Normal | 1,545 |
| Breast - Baseline — Abnormal | 8 |
| Breast - Baseline — Not done | 0 |
| Breast - EOT — Normal | 1,485 |
| Breast - EOT — Abnormal | 13 |
| Breast - EOT — Not done | 1 |
| Adnexa - Baseline — Normal | 1,549 |
| Adnexa - Baseline — Abnormal | 4 |
| Adnexa - Baseline — Not done | 0 |
| Adnexa - EOT — Normal | 1,496 |
| Adnexa - EOT — Abnormal | 2 |
| Adnexa - EOT — Not done | 1 |
| Cervix - Baseline — Normal | 1,532 |
| Cervix - Baseline — Abnormal | 21 |
| Cervix - Baseline — Not done | 0 |
| Cervix - EOT — Normal | 1,485 |
| Cervix - EOT — Abnormal | 13 |
| Cervix - EOT — Not done | 1 |
| Uterus - Baseline — Normal | 1,542 |
| Uterus - Baseline — Abnormal | 11 |
| Uterus - Baseline — Not done | 0 |
| Uterus - EOT — Normal | 1,492 |
| Uterus - EOT — Abnormal | 6 |
| Uterus - EOT — Not done | 1 |
| Vagina - Baseline — Normal | 1,545 |
| Vagina - Baseline — Abnormal | 8 |
| Vagina - Baseline — Not done | 0 |
| Vagina - EOT — Normal | 1,489 |
| Vagina - EOT — Abnormal | 8 |
| Vagina - EOT — Not done | 2 |
| External genitalia - Baseline — Normal | 1,552 |
| External genitalia - Baseline — Abnormal | 1 |
| External genitalia - Baseline — Not done | 0 |
| External genitalia - EOT — Normal | 1,497 |
| External genitalia - EOT — Abnormal | 1 |
| External genitalia - EOT — Not done | 1 |
Endometrial biopsies was obtained from a subset of subjects included in the endometrial safety substudy at the screening visit and at the end of treatment visit if the subject has completed at least 10 cycles.
| Participants | 15 mg E4/3 mg DRSP |
|---|---|
| Baseline — No tissue | 0 |
| Baseline — Tissue insufficient for diagnosis | 1 |
| Baseline — Benign histology:Atrophic | 2 |
| Baseline — Benign histology: Inactive | 7 |
| Baseline — Benign histology:Proliferative | 76 |
| Baseline — Secretory | 22 |
| Baseline — Menstrual type | 0 |
| Baseline — Simple hyperplasia without atypia | 0 |
| Baseline — Complex hyperplasia without atypia | 0 |
| Baseline — Pre-malignant/Malignant histology | 0 |
| End of Treatment — No tissue | 0 |
| End of Treatment — Tissue insufficient for diagnosis | 9 |
| End of Treatment — Benign histology:Atrophic | 11 |
| End of Treatment — Benign histology: Inactive | 61 |
| End of Treatment — Benign histology:Proliferative | 22 |
| End of Treatment — Secretory | 5 |
| End of Treatment — Menstrual type | 0 |
| End of Treatment — Simple hyperplasia without atypia | 0 |
| End of Treatment — Complex hyperplasia without atypia | 0 |
| End of Treatment — Pre-malignant/Malignant histology | 0 |
The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".
| Percentage maximum score on a scale | 15 mg E4/3 mg DRSP - Baseline Results | 15 mg E4/3 mg DRSP - End of Treatment Results |
|---|---|---|
| Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items) | 73.4 ± 12.77 | 73.8 ± 12.82 |
The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".
| Units on a scale | 15 mg E4/3 mg DRSP - Baseline Results | 15 mg E4/3 mg DRSP - End of Treatment Results |
|---|---|---|
| Satisfaction with medicine | 4.0 ± 0.78 | 4.0 ± 0.77 |
| Overall life statisfaction over the past week | 4.0 ± 0.68 | 4.0 ± 0.70 |
The MDQ is a standard method for measuring cyclical perimenstrual symptoms. The participants rated common symptoms and feelings associated with menstruation using the following scale: 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong),and 4 (present, severe) observed during pre-menstrual (4 days before menstruation), menstrual (most recent flow) and intermenstrual (remainder of the cycle) phases. Reported values are values at Cycle 13 minus values at Baseline. An overall positive change from baseline represents an increase in symptom or feeling severity.
| units on a scale | 15 mg E4/3 mg DRSP Tablet - Menstrual Phase | 15 mg E4/3 mg DRSP Tablet - Premenstrual Phase | 15 mg E4/3 mg DRSP Tablet - Intermenstrual Phase |
|---|---|---|---|
| Pain | -0.4 ± 3.6 | -0.1 ± 2.96 | -0.1 ± 2.67 |
| Water retention | -0.1 ± 2.61 | -0.1 ± 2.57 | 0.0 ± 2.09 |
| Autonomic reactions | -0.1 ± 1.42 | -0.0 ± 1.30 | -0.0 ± 1.22 |
| Negative affect | -0.4 ± 4.90 | -0.3 ± 4.70 | -0.1 ± 3.93 |
| Impaired concentration | 0.0 ± 2.67 | -0.0 ± 2.55 | 0.0 ± 2.23 |
| Behaviour change | -0.1 ± 2.86 | -0.1 ± 2.55 | -0.0 ± 1.99 |
| Arousal | -0.3 ± 3.46 | -0.3 ± 3.62 | -0.3 ± 3.91 |
| Control | 0.0 ± 1.52 | 0.0 ± 1.57 | 0.0 ± 1.63 |
Collected over From screening to end of treatment (13 months). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 15 mg E4/3 mg DRSP | 0/1,553 (0%) | 13/1,553 (0.8%) | 784/1,553 (50.5%) |
| Event | 15 mg E4/3 mg DRSP |
|---|---|
| AppendicitisInfections and infestations | 2/1553 |
| Spinal column injuryInjury, poisoning and procedural complications | 1/1553 |
| ConcussionInjury, poisoning and procedural complications | 1/1553 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/1553 |
| Migraine without auraNervous system disorders | 1/1553 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/1553 |
| PyrexiaGeneral disorders | 1/1553 |
| VertigoEar and labyrinth disorders | 1/1553 |
| Abdominal painGastrointestinal disorders | 1/1553 |
| ColitisGastrointestinal disorders | 1/1553 |
| Event | 15 mg E4/3 mg DRSP |
|---|---|
| HeadacheNervous system disorders | 120/1553 |
| MetrorrhagiaReproductive system and breast disorders | 85/1553 |
| Vaginal haemorrhageReproductive system and breast disorders | 74/1553 |
| AcneSkin and subcutaneous tissue disorders | 65/1553 |
| DysmenorrhoeaReproductive system and breast disorders | 47/1553 |
| Breast painReproductive system and breast disorders | 42/1553 |
| Libido decreasedNervous system disorders | 38/1553 |
| Weight increasedInvestigations | 36/1553 |
| Abdominal painGastrointestinal disorders | 36/1553 |
| Urinary tract infectionInfections and infestations | 30/1553 |
All participants aged 18 to 50 years who received at least one dose of 15 mg E4/3 mg DRSP
| Age, Categorical(Participants) | 15 mg E4/3 mg DRSP |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1,553 |
| >=65 years | 0 |
| Age, Continuous(years) | 15 mg E4/3 mg DRSP |
|---|---|
| Mean | 27.1 ± 6.86 |
| Sex: Female, Male(Participants) | 15 mg E4/3 mg DRSP |
|---|---|
| Female | 1,553 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | 15 mg E4/3 mg DRSP |
|---|---|
| Hispanic or Latino | 13 |
| Not Hispanic or Latino | 1540 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | 15 mg E4/3 mg DRSP |
|---|---|
| Belgium | 87 |
| Czechia | 335 |
| Finland | 181 |
| Germany | 141 |
| Hungary | 190 |
| Norway | 108 |
| Poland | 221 |
| Russia | 280 |
| Sweden | 10 |
| Body mass index(Kg/m^2) | 15 mg E4/3 mg DRSP |
|---|---|
| Mean | 23.0 ± 3.469 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Jun 2016, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estetrol · Drospirenone
Estetra